Valeant nears $1bn deal with Sprout for Libido drug Addyi
The deal will see Valeant pay all cash, one $500m installment upfront and the remaining next year to Sprout, according to the Wall Street Journal. Under the deal,
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Developed for the prescription market and formulated with the patented Microcyn Technology, the product is being made available via the company’s dermatology division IntraDerm Pharmaceuticals. Alevicyn SG Antipruritic